Frontlight ResearchEarly access
Neuroendocrine tumours trials in Italy
16 of 25 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleBelzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Where
- Bologna, Brescia, Milan, Naples, Siena, Verona
- Age
- 12 years and over
- People
- 355 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00 - Phase 3Taking peopleDAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
- Where
- Bari, Florence, Milan, Naples, Palermo, Rome, Verona
- Age
- 18 years and over
- People
- 390 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07544654 · EU 2025-523869-22-00 - Phase 2/3Taking peopleZanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Where
- Aviano, Bologna, Meldola, Milan, Naples, Orbassano to, Palermo, Roma
- Age
- 18 years and over
- People
- 440 worldwide
- Run by
- Exelixis
See details and how to joinNCT06943755 · EU 2025-521043-20-00 - Phase 1Not yet taking people in ItalyPhase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
- Where
- Milan, Naples
- Age
- 18 years to 100 years
- People
- 116 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00 - Phase 3Taking peopleStudy to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
- Where
- Ferrara, Genoa, Milan, Negrar, Pisa, Rome, Rozzano
- Age
- 12 years to 100 years
- People
- 240 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06784752 · EU 2024-518325-15-00 - Phase 3Active, not recruitingStudy Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
- Where
- Bari, Bergamo, Meldola, Milan, Rome, Verona
- Age
- 18 years and over
- People
- 156 worldwide
- Run by
- Amgen Inc.
See details and how to join2024-520050-38-00 - Phase 2CompletedDAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Where
- Ancona, Brescia, Candiolo, Milan, Parma, Rome
- Age
- 18 years and over
- People
- 204 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00 - Phase 3Taking peopleEfficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
- Where
- Bari, Meldola, Milan, Reggio Emilia, Roma, Verona
- Age
- 18 years and over
- People
- 170 worldwide
- Run by
- Grupo Espanol de Tumores Neuroendocrinos
See details and how to joinNCT05918302 · EU 2022-502154-13-00 - Phase 2Not yet taking people in ItalyReceptor radionuclide therapy with 177Lu-DOTATOC (177Lu- edotreotide or 177Lu-octreotide) in SSTR positive patients: a multicenter, prospective, phase II trial
- Where
- Cesena, Meldola
- Age
- 18 years and over
- People
- 178
- Run by
- Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
See details and how to join2024-519183-40-00 - No phaseTaking peopleUse of 68Ga-DOTATOC PET/CT-enterography for Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel
- Where
- Milan
- Age
- 18 years and over
- People
- 18
- Run by
- European Institute of Oncology
See details and how to joinNCT06773624 - Phase 2Taking peopleMetronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study
- Where
- Milan
- Age
- 18 years and over
- People
- 46
- Run by
- European Institute of Oncology
See details and how to joinNCT05554003 - Phase 2Taking peopleA Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial
- Where
- Bari, Bologna, Brescia, Milan, Naples, Orbassano, Rome, Rozzano, Verona, Viagrande
- Age
- 18 years and over
- People
- 69
- Run by
- Fondazione IRCCS Istituto Nazionale Dei Tumori
See details and how to join2024-516612-16-00 - Phase 2Taking peopleA Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.
- Where
- Meldola
- Age
- 18 years and over
- People
- 51
- Run by
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT04166006 · EU 2023-510251-31-00 - Phase 2Taking people"Receptor Radionuclide Therapy With 177Lu-DOTATOC
- Where
- Cesena, Meldola
- Age
- 18 years and over
- People
- 100
- Run by
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT06045260 - Phase 2Taking peopleA Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)
- Where
- Naples
- Age
- 18 years and over
- People
- 35
- Run by
- National Cancer Institute, Naples
See details and how to joinNCT04893785 - Phase 2Taking peopleDurvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)
- Where
- Aviano, Bari, Bologna, Florence, Lucca, Meldola, Monza, Naples, Orbassano, Padova, Parma, Roma, Rozzano, Sassari, Viagrande
- Age
- 18 years and over
- People
- 49
- Run by
- Gruppo Oncologico Italiano di Ricerca Clinica
See details and how to joinNCT06418087